OutLyzer

OutLyzer detects tumor-specific genetic variants to enable sensitive and specific identification of low allele-frequency SNVs and Indels for informing personalized cancer treatment.

Key Features:

• Tumor-specific mutation detection: Identifies mutations present in tumor samples, with emphasis on variants relevant to oncology.
• Low allele-frequency sensitivity: Detects single nucleotide variants (SNVs) and insertions/deletions (Indels) at low variant allele fractions.
• Statistical and local background evaluation: Uses statistical and local evaluation of sequencing background noise to distinguish true positive variants from false positives.
• Validated sample set: Validated on a cohort of 130 previously genotyped patients with samples enriched by capturing the exons of 22 genes.
• Benchmarking against established callers: Compared directly to HaplotypeCaller, LofreqStar, and Varscan2 using sensitivity and specificity metrics.
• Fixed limits of detection in evaluation: Evaluation applied a limit of detection of 1% for SNVs and 2% for Indels.
• Performance: Demonstrated superior sensitivity and specificity relative to the compared variant callers in the reported study.

Scientific Applications:

• Personalized oncology: Identification of tumor mutations to inform targeted therapy decisions and personalized treatment strategies.
• Detection of low-frequency variants: Characterization of subclonal or low-allele-frequency SNVs and Indels relevant to tumor heterogeneity.
• Biomarker identification: Pinpointing predictive markers within captured exons of cancer-related genes.
• Variant-caller benchmarking: Comparative evaluation of variant-calling performance using sensitivity and specificity on targeted exon captures.

Methodology:

Statistical and local evaluation of sequencing background noise; comparative evaluation using sensitivity and specificity on samples with exon capture of 22 genes from 130 previously genotyped patients, with limits of detection set at 1% for SNVs and 2% for Indels.